6,7-dimethoxy-2-((4-(4-((p-tolyloxy)methyl)-1H-1,2,3-triazol-1-yl)phenyl)sulfonyl)-1,2,3,4-tetrahydroisoquinoline | 1615201-35-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 6,7-dimethoxy-2-((4-(4-((p-tolyloxy)methyl)-1H-1,2,3-triazol-1-yl)phenyl)sulfonyl)-1,2,3,4-tetrahydroisoquinoline
• 英文别名: 6,7-dimethoxy-2-[4-[4-[(4-methylphenoxy)methyl]triazol-1-yl]phenyl]sulfonyl-3,4-dihydro-1H-isoquinoline
• CAS: 1615201-35-8
• 化学式: C₂₇H₂₈N₄O₅S
• 分子量: 520.609
• InChiKey: MDDJZHXUCXACIQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  37
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  104
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  4-nitro-N-(2-(3,4-dimethoxyphenyl)ethyl)benzenesulfonamide 在 盐酸 、 copper(ll) sulfate pentahydrate 、 tin(II) chloride dihdyrate 、 Vitamin C 、 sodium nitrite 作用下， 以 甲酸 、 乙醇 、 水 、 叔丁醇 为溶剂， 反应 6.75h， 生成 6,7-dimethoxy-2-((4-(4-((p-tolyloxy)methyl)-1H-1,2,3-triazol-1-yl)phenyl)sulfonyl)-1,2,3,4-tetrahydroisoquinoline
  参考文献：
  名称：

  Design, synthesis and molecular docking studies of novel N-benzenesulfonyl-1,2,3,4-tetrahydroisoquinoline-based triazoles with potential anticancer activity

  摘要：

  A novel series of N-benzenesulfonyl-1,2,3,4-tetrahydroisoquinolines (14-33) containing triazole moiety were designed and synthesized through rational cycloadditions using the modified Pictet-Spengler reaction and the Click chemistry. Antiproliferative activity against four cancer cell lines (e.g., HuCCA-1, HepG2, A549 and MOLT-3) revealed that many substituted triazole analogs of benzoates (20, 29) and benzaldehydes (30,32) exhibited anticancer activity against all of the tested cancer cell lines in which the ester analog 20 was shown to be the most potent compound against HuCCA-1 (IC50=0.63 mu M) and A549 (IC50 = 0.57 mu M) cell lines. Triazoles bearing phenyl (15, 24), tolyl (26, 27), acetophenone (19), benzoate (20, 29), benzaldehyde (21, 30) and naphthalenyl (25) substituents showed stronger anticancer activity against HepG2 cells than that of the etoposide. Interestingly, the p-tolyl analog (27) displayed the most potent inhibitory activity (1050 = 0.56 mu M) against HepG2 cells without affecting normal cells. Of the investigated tetrahydroisoquinoline-triazoles, the promising compounds 20 and 27 were selected for molecular docking against AKR1C3, which was identified to be a plausible target site. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.05.019

文献信息

• Design, synthesis and molecular docking studies of novel N-benzenesulfonyl-1,2,3,4-tetrahydroisoquinoline-based triazoles with potential anticancer activity
  作者：Ratchanok Pingaew、Prasit Mandi、Chanin Nantasenamat、Supaluk Prachayasittikul、Somsak Ruchirawat、Virapong Prachayasittikul

  DOI：10.1016/j.ejmech.2014.05.019

  日期：2014.6

  A novel series of N-benzenesulfonyl-1,2,3,4-tetrahydroisoquinolines (14-33) containing triazole moiety were designed and synthesized through rational cycloadditions using the modified Pictet-Spengler reaction and the Click chemistry. Antiproliferative activity against four cancer cell lines (e.g., HuCCA-1, HepG2, A549 and MOLT-3) revealed that many substituted triazole analogs of benzoates (20, 29) and benzaldehydes (30,32) exhibited anticancer activity against all of the tested cancer cell lines in which the ester analog 20 was shown to be the most potent compound against HuCCA-1 (IC50=0.63 mu M) and A549 (IC50 = 0.57 mu M) cell lines. Triazoles bearing phenyl (15, 24), tolyl (26, 27), acetophenone (19), benzoate (20, 29), benzaldehyde (21, 30) and naphthalenyl (25) substituents showed stronger anticancer activity against HepG2 cells than that of the etoposide. Interestingly, the p-tolyl analog (27) displayed the most potent inhibitory activity (1050 = 0.56 mu M) against HepG2 cells without affecting normal cells. Of the investigated tetrahydroisoquinoline-triazoles, the promising compounds 20 and 27 were selected for molecular docking against AKR1C3, which was identified to be a plausible target site. (C) 2014 Elsevier Masson SAS. All rights reserved.